Clinical trials: Dose Finding Study
Alzheimer's Disease
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group study using a Bayesian design with response adaptive randomization across placebo or 5 active arms of lecanemab to determine clinical efficacy…
- Trial name
- NCT01767311
- Testing
- Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg
- Where
- 169 sites in United States, Canada and 9 more
- Volunteers
- 856 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease (AD)
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population.
- Trial name
- Abroad (NCT05771428)
- Testing
- ABBV-552
- Where
- 64 sites in United States, Australia and 5 more
- Volunteers
- 263 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Clinical Study to Evaluate SM17 for Atopic Dermatitis
This trial is a phase 2, randomized, double-Blind, placebo-Controlled, dose-finding clinical study conducted in participants with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07445919
- Testing
- SM17 for subcutaneous injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- SinoMab BioScience Ltd
Solid Tumor
A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies
This is a multicenter, open-label, safety study. Eligible subjects will be adults with advanced malignancies. The study includes a pretreatment and treatment phase.
- Trial name
- NCT02730481
- Testing
- Oraxol
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Athenex, Inc.
Rheumatoid Arthritis
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy.
- Trial name
- NCT00928512
- Testing
- Secukinmab
- Where
- 58 sites in United States, Belgium and 9 more
- Volunteers
- 237 people
- Sponsor
- Novartis Pharmaceuticals
Renal Transplant Failure and Rejection
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease.
- Trial name
- MODERNIZE1 (NCT07508787)
- Testing
- Siplizumab, Rabbit anti-thymocyte globulin
- Where
- 24 sites in United States, Brazil and 1 more
- Volunteers
- 120 people
- Sponsor
- Nefro Avillion Clinical Development, LLC
Nocturia
A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults
The purpose of this trial was to investigate the efficacy, safety and tolerability of different oral doses of FE 201836, with desmopressin as a benchmark, during 12 weeks of treatment for nocturia due to nocturnal polyuria in…
- Trial name
- NCT03201419
- Testing
- FE 201836, Desmopressin
- Where
- 72 sites in United States, Belgium and 5 more
- Volunteers
- 302 people
- Sponsor
- Ferring Pharmaceuticals
Pain, Postoperative
Intrathecal Paracetamol Before Spinal Anaesthesia With Chloroprocaine HCl 1% for Short Knee Procedures
This is a phase II, single centre, randomised, parallel-group, double-blind, three doses, placebo-controlled, exploratory efficacy and safety study.
- Trial name
- NCT03428230
- Testing
- 30 mg Paracetamol 3% (1 mL), 60 mg Paracetamol 3% (2 mL), 90 mg Paracetamol 3% (3 mL)
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Sintetica SA
Pain, Peripheral Neuropathy
The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many chemotherapeutic agents including vincristine, paclitaxel, cisplatin, oxaliplatin, bortezomib and ixabepilone.
- Conditions
- Pain, Peripheral Neuropathy, Neuropathic Pain
- Trial name
- TTX-CINP-201 (NCT01655823)
- Testing
- Tetrodotoxin
- Where
- 23 sites in United States
- Volunteers
- 125 people
- Sponsor
- Wex Pharmaceuticals Inc.
Hypertrophic Cardiomyopathy
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by…
- Trial name
- MyPEAK-1 (NCT05836259)
- Testing
- TN-201
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tenaya Therapeutics
Rhinitis Allergic
MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)
The clinical study evaluates the efficacy and safety of MK0476 in adult patients with allergic rhinitis.
- Trial name
- NCT00446186
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 2 Weeks
- Volunteers
- 945 people
- Sponsor
- Organon and Co
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma
- Trial name
- NCT05585034
- Testing
- XmAb®808, Keytruda® (pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Xencor, Inc.
Weight Loss
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735…
- Trial name
- NCT06828055
- Testing
- VK2735
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Viking Therapeutics, Inc.
Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
This is a Phase I, prospective, dose-finding study to evaluate the safety, persistence, and clinical activity of GF-CART01 in subjects aged 18-70 with relapsed or refractory (R/R) B-cell hematological malignancies and failure of…
- Conditions
- Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory, Follicular Lymphoma ( FL), Primary Mediastinal Large B-Cell Lymphoma-Refractory
- Trial name
- CD20/19 CAR T (NCT06703892)
- Testing
- GF-CART01
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- GenomeFrontier Therapeutics TW Co., Ltd.
Resistant Hypertension
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
The purpose of this 20-week randomized double-blind study in patients with resistant hypertension (rHTN) is to evaluate the efficacy, safety, and tolerability, of different doses of XXB750 administered as subcutaneous (SC)…
- Trial name
- NCT05562934
- Testing
- XXB750 drug
- Where
- 78 sites in United States, Australia and 14 more
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Participants
A Study to Find a Suitable Dose of ASP8731 and Check for Medical Problems at Each Dose in Healthy Adults
ASP8731 is a potential new treatment for people with sickle cell disease. Before ASP8731 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body.
- Trial name
- NCT05167526
- Testing
- ASP8731
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
This is a phase l multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients.
- Conditions
- Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent
- Trial name
- NCT03853616
- Testing
- MB-CART19.1
- Where
- 9 sites in Germany
- Volunteers
- 48 people
- Sponsor
- Miltenyi Biomedicine GmbH
Metastasis, Locally Advanced Solid Tumor
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
XRD-0394 is a novel, potent, oral, small molecule dual inhibitor of ataxia telangiectasia mutated kinase (ATM) and deoxyribonucleic acid (DNA)-dependent protein kinase (DNA-PK) that has selectivity compared with other…
- Conditions
- Metastasis, Locally Advanced Solid Tumor, Recurrent Cancer
- Trial name
- NCT05002140
- Testing
- XRD-0394, Palliative radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- XRad Therapeutics Inc
Kidney Injury Following Open-Chest Cardiac Surgery
A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery
The goal of this clinical trial is to identify the optimal dose of RMC-035 for protection of long-term renal function in adult patients undergoing cardiac surgery who are at high risk of kidney injury.
- Trial name
- POINTER (NCT06475274)
- Testing
- RMC-035
- Where
- 19 sites in Canada, Czechia and 2 more
- Volunteers
- 170 people
- Sponsor
- Guard Therapeutics AB
Cancer, Neoplasm Metastasis
Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.
- Trial name
- NCT00582985
- Testing
- TRC105 chimeric anti-CD105 antibody
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Tracon Pharmaceuticals Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.